Navigation Links
Reversing aging
Date:10/17/2011

Technology developed by researchers at The University of Texas at Austin could significantly reduce the time and cost to finding a cure for Alzheimer's disease and help answer one of the greatest biological questions: why do we age?

The research, led by Cockrell School of Engineering Associate Professor Adela Ben-Yakar and College of Natural Sciences Assistant Professor Jon Pierce-Shimomura, aims to prevent degeneration of the nervous system, which occurs through natural aging and diseases like Alzheimer's.

Degeneration has become a pervasive and growing problem in the last century due to new treatments that extend lifespan but cannot prevent neurological decline. This year alone, 5.4 million Americans are living with Alzheimer's, and every 69 seconds another American develops the disease, according to the Alzheimer's Association. The toll of the disease extends beyond those living with it. It impacts their families, caretakers and society, which will pay $183 billion this year to care for people with Alzheimer's.

"We can treat cancer when we diagnose it on time and maybe find solutions for heart problems, but when it comes to the brain we don't have many effective solutions," said Ben-Yakar, from the Department of Mechanical Engineering. "[Neurodegeneration] is a big problem for all of humanity. As an engineer, it excites me to find new ways of doing things, but the end result is what really motivates me and my colleague."

Ben-Yakar and Pierce-Shimomura were selected late last month to receive a competitive $3 million Transformative Research Projects Award from the National Institutes of Health (NIH) for their research.

The grants are part of a $143.8 million funding initiative provided by NIH this year to 79 researchers around the nation, including Biomedical Engineering Professor Aaron Baker, who received the New Innovator award.

"The awards are intended to catalyze giant leaps forward for any area of bio
'/>"/>

Contact: Melissa Mixon
melissa.mixon@austin.utexas.edu
512-471-2129
University of Texas at Austin
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. New breathing therapy reduces panic and anxiety by reversing hyperventilation
2. Study reveals new possibility of reversing damage caused by MS
3. Preventing or reversing inflammation after heart attack, stroke may require 2-pronged approach
4. Reversing ecology reveals ancient environments
5. Open-access publication in JoVE receives sponsorship from Carl Zeiss MicroImaging
6. Researchers study agings effect on the brain
7. Organic medical imaging system to detect disease and track medication
8. Scripps and Complete Genomics to collaborate on genetic research study on healthy aging
9. Managing future forests for water
10. UCLA researchers develop system that finds prostate cancer spread earlier than conventional imaging
11. Scientists turn back the clock on adult stem cells aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... of dinosaurs a newly discovered hadrosaur with ... named Rhinorex condrupus by paleontologists from ... lived in what is now Utah approximately 75 ... , Rhinorex, which translates roughly into "King Nose," ... other Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs ...
(Date:9/19/2014)... new resource unveiled today by researchers from several ... Dublin provides both experienced and aspiring researchers with ... and operate robots made from soft, flexible materials. ... laser cutters, and other advances in manufacturing technology, ... field. Using principles drawn from conventional rigid robot ...
(Date:9/19/2014)... professor will study the unique bioelectric signaling system of ... people,s health. The OU researcher is working to ... produce the signals used to map the world around ... rate of 500-600 discharges a second throughout their lives. ... are extreme, but necessary for survival. , "There is ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Soft robotics 'toolkit' features everything a robot-maker needs 2
... A new type of protein discovered by Queen’s University researchers ... as those that cause food poisoning and typhoid. , ... YihE or RdoA ?a team of professors and students from ... up possibilities for new drug development. , “Our ...
... from the Virginia Commonwealth University Massey Cancer Center ... of Cancer Research's annual meeting suggesting the potential ... leukemia (CLL). , In this study, ... of translational research, interactions between bortezomib and romidepsin ...
... found astonishing evidence that the lifelong use of two ... by four years compared to people who are monolingual. ... literature examining how lifestyle factors such as physical activity, ... in later years of life. Cognitive reserve refers to ...
Cached Biology News:Protein discovery targets antibiotic-resistant bacteria 2Canadian study shows bilingualism has protective effect in delaying onset of dementia by four years 2Canadian study shows bilingualism has protective effect in delaying onset of dementia by four years 3
(Date:9/19/2014)... 19, 2014 Follow us ... to revolutionize the world has attracted diverse players ... small start-ups. The early years of nanotechnology development ... due to the high risks involved, which deterred ... for this evolving technology have been growing over ...
(Date:9/19/2014)... 19, 2014  An entire month is dedicated to ... – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease ... muscle atrophy, weakness, and foot and hand deformities. CMT ... worldwide. CMT is a progressive disease, and over time ... mobility devices such as leg braces, wheelchairs and scooters ...
(Date:9/19/2014)... September 19, 2014 Biotech companies ... of emerging drug systems and advanced Laboratory Instrumentation. Companies ... Company (NYSE: BDX ), Thermo Fisher Scientific ... (NASDAQ: RGDO ), Sangamo Biosciences Inc. (NASDAQ: ... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... 10 Bioheart, Inc., (OTC Bulletin Board: BHRT) a company ... diagnose and treat heart failure and other cardiovascular diseases announced ... development has been invited to participate in the 2009 World ... , Ms. Comella will speak on the concurrent ...
... , , , ... , Current studies show that only four ... point of care. By 2019, the Congressional Budget Office (CBO) estimates ... to about 90 percent , EHRs will create ...
... ATLANTA and LONDON, Sept. 10 CryoLife ... device and cardiovascular tissue processing company, today announced the first clinical ... received CE mark approval in August 2009. BioFoam was used in ... to promote hemostasis (a complex process that stops bleeding) by sealing ...
Cached Biology Technology:Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd 2Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd 3Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 2Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 3Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 4CryoLife Announces First Clinical Use of BioFoam(R) 2CryoLife Announces First Clinical Use of BioFoam(R) 3CryoLife Announces First Clinical Use of BioFoam(R) 4CryoLife Announces First Clinical Use of BioFoam(R) 5
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: